Mild Cognitive Impairment (MCI) Clinical Trial
Official title:
Preventing Cognitive Decline in African Americans With Mild Cognitive Impairment
Verified date | November 2018 |
Source | Thomas Jefferson University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The goal of this study is to determine whether increasing participation in cognitive, physical, and/or social activities prevents cognitive decline in older African Americans (AAs) with Mild Cognitive Impairment (MCI). Patients with MCI are at increased risk for Alzheimer's Disease (AD); we propose that increasing participation in activities will prevent cognitive decline and may delay the onset of Alzheimer's Disease (AD). We will test this hypothesis by conducting a clinical trial in which older AAs with MCI (aged 65 years and older) will be randomized to Behavior Activation (BA) (a behavioral intervention that increases participation in daily activities) or Supportive Therapy (ST) (a person-centered psychotherapy that involves active listening and offering support focusing on participants' problems and concerns). We hypothesize that BA-treated subjects will have fewer declines in cognitive and functional abilities, fewer depressive and neuropsychiatric symptoms, and better quality of life than ST-treated subjects at 24 months.
Status | Completed |
Enrollment | 221 |
Est. completion date | December 13, 2016 |
Est. primary completion date | December 13, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 65 Years and older |
Eligibility |
Inclusion Criteria: - Age 65 years and older - Having a friend/relative willing to serve as a Knowledgeable Informant (KI) - Diagnosis of aMCI-MD - Self-identified as African American Exclusion Criteria: - Psychiatric diagnosis, including dementia and major depression - Sensory deficits that preclude neuropsychological testing - Institutional residence - Reduced life expectancy due to known terminal illness |
Country | Name | City | State |
---|---|---|---|
United States | Thomas Jefferson University | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Thomas Jefferson University | Dartmouth College, Johns Hopkins University, National Institute on Aging (NIA), University of Pennsylvania |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants With a Decline of 6 Points on the Hopkins Verbal Learning Test-Revised (HVLT-R) | A decline of 6 points from baseline to 24 months on the Hopkins Verbal Learning Test-Revised (HVLT-R). Possible scores range from 0 to 12, with higher scores indicating better memory. | 24 months | |
Secondary | Change in University of California Performance-based Skills Assessment (UPSA) Score Per Year | The University of California Performance-based Skills Assessment (UPSA) was used as an objective test of accuracy with writing checks, making change, using a telephone, and scheduling a physician appointment (higher scores indicate better function). Possible scores range from 0 to 100. | 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00934531 -
Donepezil and the Risk of Falls in Seniors With Cognitive Impairment
|
N/A | |
Withdrawn |
NCT05033912 -
A Study of CST-2032 in Subjects With Cognitive Impairment
|
Phase 1 | |
Recruiting |
NCT02854033 -
Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3)
|
||
Completed |
NCT01902004 -
Brain Aging and Treatment Response in Geriatric Depression
|
Phase 4 | |
Completed |
NCT01212692 -
Effects of Mental Stimulation in Patients With Mild Cognitive Impairment
|
Phase 2 | |
Recruiting |
NCT00544791 -
The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment
|
Phase 2 | |
Withdrawn |
NCT04055532 -
Biomarkers in Neurodegenerative Diseases
|
||
Terminated |
NCT02180529 -
The Effects of Methylphenidate on the Cognitive Function of Older People With Mild Cognitive Impairment
|
N/A | |
Completed |
NCT05108922 -
A Study of Donanemab (LY3002813) Compared With Aducanumab in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 4)
|
Phase 3 | |
Recruiting |
NCT05865340 -
To Exam the Efficacy of Oral Health and Mediterranean Diet Interventions in Preventing Cognitive Decline Among Older Adults With Mild Cognitive Impairment
|
N/A | |
Recruiting |
NCT06453941 -
Yizhi Baduanjin for Patients With Cognitive Impairment
|
N/A | |
Completed |
NCT06417034 -
Hand Training Device For Cognitive Care
|
N/A | |
Completed |
NCT02110043 -
Modulation of Visual-Spatial Learning in Patients With Mild Cognitive Impairment (MCI) by tDCS
|
N/A | |
Completed |
NCT01383161 -
18-Month Study of Memory Effects of Curcumin
|
Phase 2 | |
Withdrawn |
NCT05321498 -
Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation
|
Phase 2 | |
Completed |
NCT04748666 -
PST for Care Partners of Adults With Alzheimer's and Alzheimer'S-related Dementia
|
N/A | |
Recruiting |
NCT03138018 -
Aging Stereotypes and Prodromal Alzheimer's Disease
|
N/A | |
Withdrawn |
NCT01891383 -
Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel
|
||
Recruiting |
NCT03448055 -
Nutritional Intervention With the Dietary Supplement, Immunocal® in MCI Patients: Promotion of Brain Health
|
N/A | |
Completed |
NCT01231971 -
Alzheimer's Disease Neuroimaging Initiative 2
|